MX2021015756A - Polimorfos de un inhibidor de cinasas macrociclicas. - Google Patents
Polimorfos de un inhibidor de cinasas macrociclicas.Info
- Publication number
- MX2021015756A MX2021015756A MX2021015756A MX2021015756A MX2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A MX 2021015756 A MX2021015756 A MX 2021015756A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphs
- kinase inhibitor
- macrocyclic kinase
- mammals
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta divulgación se refiere a polimorfos de (3aR,11S,20aS)-7-fluor o-11-metil-2,3,3a, 12,13,20a-hexahidro-1H, 5H-17,19-(meteno)ciclop enta[5,6][1,4]oxazino[3,4-i]pirazolo[4,3-f] pirido[3,2-l][1,4,8,10 ]oxatriazaciclotridecina-14(11H)-ona que son útiles en el tratamiento de enfermedades, como el cáncer, en mamíferos. Esta divulgación también se refiere a composiciones que incluyen tales polimorfos y a métodos para usar tales composiciones en el tratamiento de enfermedades, tales como cáncer, en mamíferos, especialmente en humanos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863493P | 2019-06-19 | 2019-06-19 | |
US202062959940P | 2020-01-11 | 2020-01-11 | |
US202063036102P | 2020-06-08 | 2020-06-08 | |
PCT/US2020/037892 WO2020257169A1 (en) | 2019-06-19 | 2020-06-16 | Polymorphs of a macrocyclic kinase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015756A true MX2021015756A (es) | 2022-01-27 |
Family
ID=74040102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015756A MX2021015756A (es) | 2019-06-19 | 2020-06-16 | Polimorfos de un inhibidor de cinasas macrociclicas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220411439A1 (es) |
EP (1) | EP3986413A4 (es) |
JP (1) | JP2022537385A (es) |
KR (1) | KR20220046549A (es) |
CN (1) | CN114025765A (es) |
AU (1) | AU2020294627A1 (es) |
BR (1) | BR112021025786A2 (es) |
CA (1) | CA3143043A1 (es) |
CO (1) | CO2022000405A2 (es) |
IL (1) | IL288982A (es) |
MX (1) | MX2021015756A (es) |
PE (1) | PE20220135A1 (es) |
TW (1) | TW202115090A (es) |
WO (1) | WO2020257169A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113336774B (zh) * | 2021-06-25 | 2023-05-23 | 江南大学 | 作为trk抑制剂的取代的手性二芳基大环化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110317214B (zh) * | 2014-01-24 | 2022-11-22 | 特普医药公司 | 作为蛋白质激酶的调节剂的二芳基巨环 |
AU2016287568B2 (en) * | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
EP4397665A3 (en) * | 2015-07-06 | 2024-08-21 | Turning Point Therapeutics, Inc. | Diaryl macrocycle polymorph |
AU2016296878B2 (en) * | 2015-07-21 | 2020-12-17 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
UY37808A (es) * | 2017-07-14 | 2019-02-28 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 |
ES2929467T3 (es) | 2017-12-19 | 2022-11-29 | Turning Point Therapeutics Inc | Compuestos macrocíclicos para tratar enfermedades |
-
2020
- 2020-06-16 AU AU2020294627A patent/AU2020294627A1/en not_active Abandoned
- 2020-06-16 EP EP20826665.0A patent/EP3986413A4/en active Pending
- 2020-06-16 WO PCT/US2020/037892 patent/WO2020257169A1/en unknown
- 2020-06-16 JP JP2021575515A patent/JP2022537385A/ja not_active Withdrawn
- 2020-06-16 CN CN202080044953.1A patent/CN114025765A/zh active Pending
- 2020-06-16 KR KR1020227001994A patent/KR20220046549A/ko unknown
- 2020-06-16 CA CA3143043A patent/CA3143043A1/en active Pending
- 2020-06-16 PE PE2021002184A patent/PE20220135A1/es unknown
- 2020-06-16 US US17/618,060 patent/US20220411439A1/en active Pending
- 2020-06-16 BR BR112021025786A patent/BR112021025786A2/pt not_active Application Discontinuation
- 2020-06-16 MX MX2021015756A patent/MX2021015756A/es unknown
- 2020-06-19 TW TW109120778A patent/TW202115090A/zh unknown
-
2021
- 2021-12-14 IL IL288982A patent/IL288982A/en unknown
-
2022
- 2022-01-19 CO CONC2022/0000405A patent/CO2022000405A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20220135A1 (es) | 2022-01-27 |
IL288982A (en) | 2022-02-01 |
JP2022537385A (ja) | 2022-08-25 |
AU2020294627A1 (en) | 2022-02-17 |
CA3143043A1 (en) | 2020-12-24 |
KR20220046549A (ko) | 2022-04-14 |
CO2022000405A2 (es) | 2022-04-29 |
CN114025765A (zh) | 2022-02-08 |
EP3986413A4 (en) | 2023-06-14 |
WO2020257169A1 (en) | 2020-12-24 |
BR112021025786A2 (pt) | 2022-02-01 |
US20220411439A1 (en) | 2022-12-29 |
TW202115090A (zh) | 2021-04-16 |
EP3986413A1 (en) | 2022-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4397665A3 (en) | Diaryl macrocycle polymorph | |
MX2018000718A (es) | Macrociclos de diarilo quirales y usos de los mismos. | |
MX2021011438A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. | |
WO2018141002A3 (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
PH12016502115B1 (en) | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | |
PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
EP3489238B8 (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
MX2023000782A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
WO2006107771A3 (en) | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
WO2017103670A8 (en) | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors | |
EA201892518A1 (ru) | ЗАМЕЩЕННЫЕ 5,6,7,8-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИН-3(2H)-ОН И 2,5,6,7-ТЕТРАГИДРО-3H-ПИРРОЛО[2,1-c][1,2,4]ТРИАЗОЛ-3-ОН И ИХ ПРИМЕНЕНИЕ | |
NZ629230A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
MX2023007162A (es) | Macrociclos y sus usos. | |
WO2018038988A3 (en) | Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them | |
TW200745102A (en) | Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof | |
MX2023000503A (es) | Macrociclos y su uso. | |
MX2015000336A (es) | Inhibidores de la enzima fosfodiesterasa 10. | |
WO2009111354A3 (en) | Tyrosine kinase inhibitors | |
MX2018004517A (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). | |
MX2021015756A (es) | Polimorfos de un inhibidor de cinasas macrociclicas. | |
MA31630B1 (fr) | Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
EP4279489A4 (en) | USE OF PYRIDO[1,2-A PYRIMIDINONE ANALOGUES |